ABSTRACT
Background Injection drug use-associated bacterial and fungal infections are increasingly common, and social contexts shape individuals’ injecting practices and treatment experiences. We sought to synthesize qualitative studies of social-structural factors influencing incidence and treatment of injecting-related infections.
Methods We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO from January 1, 2000, to February 18, 2021. Informed by Rhodes’ “risk environment” framework, we performed thematic synthesis in three stages: (1) line-by-line coding; (2) organizing codes into descriptive themes, reflecting interpretations of study authors; (3) consolidating descriptive themes into conceptual categories to identify higher-order analytic themes.
Results We screened 4,841 abstracts and included 26 qualitative studies on experiences of injecting-related bacterial and fungal infections. We identified six descriptive themes organized into two analytic themes. The first analytic theme, social production of risk, considered macro-environmental influences. Four descriptive themes highlighted pathways through which this occurs: (1) unregulated drug supply, leading to poor drug quality and solubility; (2) unsafe spaces, influenced by policing practices and insecure housing; (3) health care policies and practices, leading to negative experiences that discourage access to care; and (4) harm reduction programs, including structural barriers to effective service provision. The second analytic theme, practices of care among people who inject drugs, addresses protective strategies that people who inject drugs employ within infection risk environments. Associated descriptive themes were: (5) mutual care, including assisted-injecting and sharing sterile equipment; and (6) self-care, including vein health and self-treatment. Within constraining risk environments, some protective strategies for bacterial infections precipitated other health risks (e.g., HIV transmission).
Conclusions Injecting-related bacterial and fungal infections are shaped by modifiable social-structural factors, including unregulated drug quality, criminalization, insufficient housing, limited harm reduction services, and harmful health care practices. Enabling environment interventions that address these factors could further empower people who inject drugs to protect themselves and their community.
Competing Interest Statement
MB reports personal fees from AbbVie, a pharmaceutical research and development company, and grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of the submitted work. The other authors report no competing interests.
Clinical Protocols
https://bmjopen.bmj.com/content/11/8/e049924
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=231411
Funding Statement
TDB is supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a Canadian Institutes of Health Research Fellowship (CIHR-FRN# 171259), and through the Research in Addiction Medicine Scholars Program (National Institutes of Health/ National Institute on Drug Abuse; R25DA033211). For part of this work, he was supported by the Killam Postgraduate Scholarship, Ross Stewart Smith Memorial Fellowship in Medical Research, and Clinician Investigator Programme Graduate Stipend (all from Dalhousie University Faculty of Medicine). MB, EC, and IK were supported in this work via the Ross Stewart Smith Memorial Fellowship in Medical Research (PI: TDB). DL was funded by a National Institute of Health Research Doctoral Research Fellowship (DRF-2018-11-ST2-016). MH was funded by a National Institute of Health Research Career Development Fellowship (CDF-2016-09-014). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. These funders had no role in the conduct or reporting of the research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
